14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CELU vs FGEN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
FGEN Captures Overall Composite Edge (61.2 BUY vs 42.9 HOLD), While CELU Leads 3–2 on Growth & Valuation Pillars
FGEN Overall Winner
6-Pillar Tally: CELU 3 – 2 FGEN (1 Tie)
Matrix Metrics: CELU 1 – 9 FGEN
As of Nov 20, 2026, FibroGen, Inc (FGEN) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (61.2/100 BUY vs. 42.9/100 HOLD) after splitting the core matrix 9–1 (led by Valuation Multiples, Growth & Scale), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. CELU trades at $0.46 (N/M Forward P/E, -254.0% operating margin) versus FGEN at $9.71 (61.4x Forward P/E, -499.1% operating margin).
Growth vs. Quality Trade-Off: FGEN earns the overall head-to-head edge with a stronger Unified Composite Score (61.2/100 BUY vs. CELU 42.9/100 HOLD) and -20.79β · 102% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile FGEN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 59.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CELU vs FGEN. Trailing 12-month operating profitability (CELU -254.0% vs FGEN -499.1%) and valuation multiples (CELU N/M vs FGEN 61.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $36.5M market capitalization and -499.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CELU vs FGEN Key Questions & Quantitative Answers
As of Nov 20, 2026, FibroGen, Inc (FGEN) captures the overall head-to-head institutional edge over Celularity Inc. (CELU) on higher Unified Composite conviction (61.2/100 BUY vs. 42.9/100 HOLD) after splitting the core matrix 9–1 (led by Valuation Multiples, Growth & Scale), while CELU wins 3–2 across the 6-pillar growth and valuation breakdown. CELU trades at $0.46 (N/M Forward P/E, -254.0% operating margin) versus FGEN at $9.71 (61.4x Forward P/E, -499.1% operating margin). Growth vs. Quality Trade-Off: FGEN earns the overall head-to-head edge with a stronger Unified Composite Score (61.2/100 BUY vs. CELU 42.9/100 HOLD) and -20.79β · 102% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile FGEN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 59.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FGEN leads the Growth & Scale pillar: CELU posts -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin), compared with FGEN at +774.8% YoY revenue growth and +53.6% YoY earnings growth on $8.3M TTM revenue (N/A gross margin, -499.1% operating margin). On trailing 12-month operating scale, CELU generates $19M in USD-normalized revenue versus $8.3M for FGEN. In operating R&D and SG&A reinvestment, CELU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FGEN.
FGEN screens cheaper on headline valuation multiples. CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin), whereas FGEN trades at 61.4x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELU (-6367.2% ROE) versus FGEN (-1015.8% ROE) capital efficiency.
In options market volatility and institutional positioning, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk). By comparison, FGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.79β · 102% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.